| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | RNA-Based Therapies | Cardiovascular System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | RNA-Based Therapies | Cardiovascular System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | RNA-Based Therapies | Cardiovascular System |
Recent Updates
Recently added Catalysts
Alnylam Pharmaceuticals, Inc.$298.76
-14.03 (-4.49%)
B 74Pipeline Score Fair Value Pharma · Commercial
Market Cap
38.20 B
EPS
4.36
P/E Ratio
67.98 $
Value Trade
287.70 M
SEC Financials
Q4 2025Dilution Risk
Revenue
1.10 B
R&D Expenses
372.22 M
Operating CF
131.02 M
Total Assets
4.97 B
Total Liabilities
4.18 B
Equity
789.18 M
D/E Ratio
12,345
0.91 %
Week
-3.56 %
1 Month
-11.63 %
3 Month
-33.64 %
6 Month
110.45 %
5 Year
4,776.23 %
All Time
Cash Data
Cash Position
2.91 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Feb 12, 2026
Overview
Volume
2.54 M
52 Week Range
284.28 - 495.55
% held by Insiders
0.43 %
% held by Institutions
98.88 %
Enterprise Value
38.16 B
Total Shares
132.56 M
Short %
4.38 %
Float Shares
132.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alnylam Pharmaceuticals, Inc.
780Total events
22Upcoming
310Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 22
Q4 2027
T3Manufacturing Milestone
Planned $250M expansion of Norton manufacturing facility to add enzymatic ligation platform
2026-H1
T2Enrollment Complete
Expect to complete enrollment in cAPPricorn-1 Phase 2 trial of mivelsiran
2026-H1
T2Trial Initiation
Expect to initiate Phase 2 trial of ALN-6400 in a second bleeding disorder
2026-H2
T1Topline Readout
Clinical de-risking data from Phase 1 study of ALN-TTRsc04 in second half 2026
2026-H2
T1Topline Readout
Clinical de-risking data from Phase 2 study of ALN-HBV02 in second half 2026
Event history 758
Jun 25, 2026
▲Partnership / LicenseCorporate
Komodo expands strategic partnership with Alnylam to scale AI-powered intelligence platform
Jun 11, 2026
▲Partnership / LicenseCorporate
GENESIS Pharma expands strategic commercial collaboration with Alnylam to Scandinavian countries
Jun 10, 2026
▲Partnership / LicenseCorporate
GENESIS Pharma expands strategic commercial partnership with Alnylam to Nordic region
Jun 9, 2026
Jun 3, 2026
▲Partnership / LicenseCorporate
Alnylam and Inceptive form strategic AI collaboration to accelerate RNAi therapeutic discovery
May 13, 2026
▲Oral PresentationVutrisiranApprovedPresentation
Neue Datenanalysen zu Vutrisiran bei ATTR-CM auf Heart Failure 2026 präsentiert
ATTR-CMsource ↗
May 13, 2026
May 12, 2026
▲Oral PresentationVutrisiranApprovedPresentation
Pooled analysis of over 25,000 patient-years of safety data for TTR-silencing RNAi therapies presented
ATTR-CMsource ↗
May 12, 2026
●Trial InitiationVutrisiranApprovedTrial
DemonsTTRate study design presented; expected to enroll >2,000 patients with up to 5 years follow-up
ATTR-CMsource ↗
May 11, 2026
◆Oral PresentationVutrisiranApprovedPresentation
Treatment with Transthyretin-Lowering RNA Interference Therapeutics is Not Associated with Ocular or Other Clinical Events Due to Vitamin A Reduction: Pooled Analysis of Vutrisiran and Patisiran Data
ATTR-CMsource ↗
May 10, 2026
◆Oral PresentationVutrisiranApprovedPresentation
Design and Rationale of DemonsTTRate: A Global, Long-Term Observational Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
ATTR-CMsource ↗
May 5, 2026
◆Oral PresentationVutrisiranApprovedPresentation
Presentatie nieuwe analyses op Heart Failure 2026
ATTR-CMsource ↗
Drug Pipeline Intelligence
B74
Pipeline Score $13.8B
Pipeline ValueFair Value
Valuation Signal29
Drugs Scored1.2x
rNPV / MCap Top 95%
Mid Cap (rank 47 of 912)
Percentile RankAlnylam Pharmaceuticals, Inc. holds a solid B-grade pipeline (74/100), with $16.2B risk-adjusted pipeline value, led by Zilebesiran in High Risk Cardiovascular Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zilebesiran Small molecule | High Risk Cardiovascular Disease | Phase 3 | NCT07181109 | 43% | $5.8B | RECRUITING | 11,000 | VERY_FAST | B (74) | Sep 30, 2030 | MODERATE_RISK | LOW Jul 10, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Vutrisiran | ATTR-CM | Phase 3 | 2026-05-12 | significantly reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events compared with placebo; slowing the progressive decline in SBP observed over time Read More | New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden Read More | |
Vutrisiran | ATTR-CM | Phase 3 | 2026-05-12 | significantly reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events compared with placebo; slowing the progressive decline in SBP observed over time Read More | New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden Read More | |
Vutrisiran | ATTR-CM | Phase 3 | 2026-05-12 | significantly reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events compared with placebo; slowing the progressive decline in SBP observed over time Read More | New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALNY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALNY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALNYKomodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
Komodo has expanded its strategic partnership with Alnylam Pharmaceuticals to enhance its AI-powered intelligence platform. This collaboration aims to leverage advanced analytics to improve healthcare outcomes. The details of the expansion and its implications for both companies were not specified in the article.
Read more →ALNYAlnylam to Host Tenth “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals is set to host the tenth installment of its 'RNAi Roundtable' webcast series. This event aims to engage stakeholders in discussions about RNA interference technology and its applications. Further details about the webcast, including speakers and topics, have not been provided in the article.
Read more →ALNYGENESIS Pharma étend son partenariat commercial stratégique avec Alnylam Pharmaceuticals dans le domaine des thérapies fondées sur l'ARNi à la région nordique
GENESIS Pharma has extended its strategic commercial partnership with Alnylam Pharmaceuticals to focus on RNAi-based therapies in the Nordic region. This partnership aims to enhance the availability and development of innovative treatments in this area. The collaboration reflects a commitment to advancing healthcare solutions.
Read more →ALNYGENESIS Pharma erweitert strategische Vertriebspartnerschaft mit Alnylam Pharmaceuticals bei RNAi-Therapeutika auf skandinavische Länder
GENESIS Pharma has expanded its strategic distribution partnership with Alnylam Pharmaceuticals to include Scandinavian countries for RNAi therapeutics. This partnership aims to enhance the availability of innovative treatments in the region. The collaboration reflects a commitment to advancing RNAi technology in new markets.
Read more →ALNYRiassunto: GENESIS Pharma espande ad alcuni paesi scandinavi la collaborazione commerciale strategica con Alnylam Pharmaceuticals in materia di terapie RNAi
GENESIS Pharma has expanded its strategic commercial collaboration with Alnylam Pharmaceuticals to include certain Scandinavian countries. This partnership focuses on RNAi therapies, enhancing the reach and availability of these treatments in the region. The collaboration aims to leverage both companies' strengths in the biopharmaceutical sector.
Read more →ALNYSamenvatting: GENESIS Pharma breidt strategisch commercieel partnerschap met Alnylam Pharmaceuticals voor RNAi-therapieën uit naar de Scandinavische regio
GENESIS Pharma is expanding its strategic commercial partnership with Alnylam Pharmaceuticals to include RNAi therapies in the Scandinavian region. This move aims to enhance the availability of innovative treatments in this market. The partnership reflects a growing interest in RNAi therapies and their potential impact on healthcare in Scandinavia.
Read more →ALNYResumen: GENESIS Pharma amplía su asociación comercial estratégica con Alnylam Pharmaceuticals para los tratamientos basados en ARNi a la región nórdica
GENESIS Pharma has expanded its strategic commercial partnership with Alnylam Pharmaceuticals to enhance the availability of RNAi-based treatments in the Nordic region. This collaboration aims to leverage both companies' strengths to improve patient access to innovative therapies. Further details on the specific treatments involved were not disclosed.
Read more →ALNYGENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
GENESIS Pharma has expanded its strategic partnership with Alnylam Pharmaceuticals to enhance the commercialization of RNAi therapeutics in the Nordic region. This collaboration aims to leverage both companies' strengths to improve patient access to innovative treatments. The partnership reflects a commitment to advancing RNAi technology in new markets.
Read more →ALNYAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam Pharmaceuticals has announced a strategic collaboration with Inceptive to leverage artificial intelligence in the discovery of RNA interference (RNAi) therapeutics. This partnership is expected to enhance the efficiency and effectiveness of developing new RNAi-based treatments. The collaboration highlights the growing trend of integrating AI in biopharmaceutical research.
Read more →ALNYAlnylam Issues 2025 Corporate Responsibility Report
Alnylam Pharmaceuticals has released its 2025 Corporate Responsibility Report. The report outlines the company's commitment to sustainability and ethical practices. However, specific details regarding the content of the report are not provided in the article.
Read more →ALNYDe nouvelles analyses de données présentées lors du congrès Heart Failure 2026 démontrent les bénéfices cliniques solides et constants du vutrisiran en tant qu’option thérapeutique de première intention chez toutes les populations
The article discusses new data analyses presented at the Heart Failure 2026 congress, highlighting the strong and consistent clinical benefits of vutrisiran as a first-line therapeutic option for all patient populations. This reinforces the drug's potential in treating heart failure effectively.
Read more →ALNYHeart Failure 2026: Neue Datenanalysen belegen robusten und konsistenten klinischen Nutzen von Vutrisiran als Erstlinien-Behandlungsoption für ATTR-CM-Patientenpopulationen – auch bei hoher Krankheitslast
The article discusses new data analyses regarding Vutrisiran as a first-line treatment option for patients with ATTR-CM. It highlights the clinical benefits observed in patient populations with high disease burden. However, specific details about the data or analyses are not provided.
Read more →ALNYSamenvatting: Nieuwe gegevensanalyses die zijn gepresenteerd tijdens Heart Failure 2026 tonen een robuust en consistent klinisch voordeel aan van vutrisiran als eerstelijnsbehandelingsoptie bij alle patiëntengroepen met ATTR-CM, inclusief patiënten met een hoge...
Recent analyses presented at Heart Failure 2026 highlight the strong clinical advantages of vutrisiran as a first-line treatment option for all patient groups with ATTR-CM. The data suggests that vutrisiran provides consistent benefits, particularly for patients with high-risk factors. This positions vutrisiran as a significant advancement in the management of this condition.
Read more →ALNYRiassunto: Le nuove analisi dei dati presentate al congresso Heart Failure 2026 dimostrano un beneficio clinico notevole e costante di vutrisiran come opzione terapeutica di prima linea in tutte le popolazioni di pazienti affetti da ATTR-CM, compresi quelli...
Recent analyses presented at the Heart Failure 2026 congress highlight the substantial and consistent clinical benefits of vutrisiran as a first-line therapeutic option for all patient populations affected by ATTR-CM. This positions vutrisiran favorably in the treatment landscape for this condition.
Read more →ALNYResumen: Los nuevos análisis de datos presentados en Heart Failure 2026 demuestran un beneficio clínico importante y consistente de vutrisiran como opción terapéutica de primera línea en todas las poblaciones de pacientes con ATTR-CM, incluyendo aquellos...
Recent data presented at Heart Failure 2026 highlights the clinical benefits of vutrisiran as a first-line therapeutic option for patients with ATTR-CM. The analysis indicates consistent positive outcomes across various patient populations. This positions vutrisiran as a promising treatment for this condition.
Read more →ALNYNew Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
The article discusses new data analyses presented at Heart Failure 2026 regarding Vutrisiran as a first-line treatment for ATTR-CM patients. The findings suggest that Vutrisiran offers robust and consistent clinical benefits across diverse patient populations, including those with a high disease burden. However, specific details about the data or outcomes are not provided.
Read more →ALNYAlnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals will present company overviews at two upcoming investor conferences: the BofA Securities Healthcare Conference on May 13, 2026, and the Goldman Sachs Annual Healthcare Conference on June 9, 2026. Live audio webcasts of the presentations will be available on the company's website, with replays accessible within 48 hours post-event.
Read more →ALNYAlnylam présentera de nouvelles analyses lors du congrès Heart Failure 2026, soulignant le profil clinique constant du vutrisiran dans l’ATTR-CM
Alnylam Pharmaceuticals will present new analyses at the Heart Failure Congress 2026, focusing on the consistent clinical profile of vutrisiran in ATTR-CM. This presentation aims to highlight the drug's performance and relevance in treating this condition. Further details about the analyses and their implications are expected during the congress.
Read more →ALNYAlnylam präsentiert auf der „Heart Failure 2026“ neue Analysen, die das konsistente klinische Profil von Vutrisiran bei ATTR-CM unterstreichen
Alnylam presented new analyses at the 'Heart Failure 2026' conference, highlighting the consistent clinical profile of Vutrisiran in treating ATTR-CM. The presentation aims to reinforce the drug's efficacy and safety in managing this condition. Further details on the analyses and their implications were not provided in the article.
Read more →ALNYSamenvatting: Alnylam presenteert nieuwe analyses op Heart Failure 2026 die consistent klinisch profiel van vutrisiran bij ATTR-CM onderstrepen
Alnylam has presented new analyses at the Heart Failure 2026 conference, emphasizing the consistent clinical profile of vutrisiran in treating ATTR-CM. The findings aim to reinforce the drug's efficacy and safety in this specific patient population. Further details on the analyses were not disclosed in the article.
Read more →ALNYResumen: Alnylam presentará nuevos análisis en Heart Failure 2026 que refuerzan la consistencia del perfil clínico de vutrisirán en la ATTR-CM
Alnylam plans to present new analyses at Heart Failure 2026 that support the clinical profile consistency of vutrisiran in ATTR-CM. The details of these analyses are currently limited, but they aim to reinforce the therapeutic potential of vutrisiran in treating this condition.
Read more →ALNYRiassunto: Alnylam presenterà nuove analisi all'Heart Failure 2026 sottolineando il profilo clinico di Vutrisiran nella ATTR-CM
Alnylam Pharmaceuticals is set to present new analyses regarding Vutrisiran at the Heart Failure 2026 conference. The focus will be on the clinical profile of Vutrisiran in treating ATTR-CM. This presentation aims to highlight the drug's potential benefits in heart failure management.
Read more →ALNYAlnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Alnylam Pharmaceuticals is set to present new analyses at the Heart Failure 2026 conference. The focus will be on the consistent clinical profile of Vutrisiran in treating ATTR-CM. This presentation aims to highlight the drug's effectiveness and reliability in managing heart failure associated with this condition.
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals reported strong financial results for Q1 2026, achieving over $1 billion in product revenues. The company is advancing its RNAi therapeutics pipeline, including three Phase 3 trials and a new Phase 1 study for obesity. Notably, the TRITON-CM study of nucresiran is expanding enrollment due to faster-than-expected patient recruitment.
Read more →ALNYAlnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
Alnylam Pharmaceuticals will report its first quarter 2026 financial results on April 30, 2026. A conference call will follow at 8:30 am ET to discuss the results and future expectations. The event will be available via a live audio webcast on the company’s website, with an archived version accessible later.
Read more →ALNYNew Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
The article mentions new data presented at ACC.26 regarding Vutrisiran's benefits in treating ATTR-CM and highlights Zilebesiran's potential for hypertension management. However, specific details about the data or outcomes are not provided.
Read more →ALNYAlnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Alnylam Pharmaceuticals has announced a strategic collaboration with Viz.ai to enhance care for patients with ATTR-CM. This partnership aims to leverage advanced technology to improve patient outcomes. Additionally, Alnylam is supporting the American Heart Association, indicating a commitment to cardiovascular health.
Read more →ALNYAlnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
Alnylam has partnered with Tenaya Therapeutics to explore new genetic targets for heart disease, with a deal worth up to $1.13 billion. Alnylam will pay $10 million upfront and cover costs during a two-year validation period. Tenaya will utilize its platform to identify up to 15 gene targets, while Alnylam will manage development and commercialization. This collaboration highlights a resurgence in cardiovascular research.
Read more →ALNYAlnylam Receives Positive Recommendation From Canada’s Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis
Alnylam Pharmaceuticals has received a positive recommendation from Canada's Drug Agency for the public reimbursement of AMVUTTRA®, an RNAi therapeutic for treating cardiomyopathy in adult patients with ATTR amyloidosis. This recommendation follows the drug's recent authorization by Health Canada and is backed by favorable results from the HELIOS-B Phase 3 study. AMVUTTRA® aims to target the root cause of the disease, offering a new treatment option that could enhance patient outcomes.
Read more →ALNYAlnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
Alnylam Pharmaceuticals will present a company overview at the TD Cowen 46th Annual Healthcare Conference on March 2, 2026. The presentation will be available via a live audio webcast on the company's website, with a replay accessible shortly after. Alnylam continues to lead in RNAi therapeutics and has a strong pipeline of medicines.
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals reported strong financial results for Q4 and full year 2025, highlighted by the approval of AMVUTTRA for ATTR-CM, which significantly boosted revenues. The company initiated three Phase 3 studies and expanded its pipeline, while also launching a new manufacturing platform. Alnylam aims to achieve ambitious goals under its Alnylam 2030 strategy to enhance patient impact and shareholder value.
Read more →ALNYAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
Alnylam Pharmaceuticals will report its financial results for the fourth quarter and full year 2025 on February 12, 2026. A conference call is scheduled for the same day at 8:30 am ET, where management will discuss these results and future expectations. The event will be accessible via a live audio webcast.
Read more →ALNY▼ -6.9%on this news
Alnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Launches " Alnylam 2030 " Strategy to Drive Next Era of Growth and Patient Imp
Alnylam Pharmaceuticals has announced its new five-year strategic plan, 'Alnylam 2030,' which aims to drive growth and improve patient impact, focusing on leadership in ATTR amyloidosis. The company forecasts a significant increase in net product revenues, predicting $2.987 billion for 2025, driven by initiatives in their TTR portfolio. Key goals include launching new therapies and scaling operations while maintaining financial discipline. Alnylam's robust pipeline and commitment to innovation position it well for future growth and impact in healthcare.
Read more →ALNYAlnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
Alnylam Pharmaceuticals plans to invest $250 million to expand its manufacturing facility in Norton, Massachusetts, aiming to create the first dedicated siRNA enzymatic-ligation manufacturing site. This expansion will enhance production capacity and reduce costs, supporting the development of new RNAi therapeutics. The siRELIS platform has been accepted into the FDA's Emerging Technology Program, facilitating regulatory discussions.
Read more →ALNYAlnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Alnylam Pharmaceuticals has announced a partial repurchase of its 1.00% Convertible Senior Notes due 2027, amounting to approximately $34.4 million. The total repurchase cost is expected to be around $51.9 million, with adjustments based on the company's stock price. Following this transaction, approximately $362.8 million of the Notes will remain outstanding.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Announces Changes to Board of Directors - Mike Bonney and Carolyn Be
Alnylam Pharmaceuticals announced changes to its Board of Directors, including the departure of Mike Bonney and Carolyn Bertozzi, effective December 2, 2025. The new independent director, Stuart Arbuckle, is set to join the board on January 5, 2026, bringing significant experience from his previous roles in biopharmaceuticals. The organization recognizes the contributions of the departing directors while emphasizing its ongoing commitment to developing RNAi therapeutics and expanding its global reach. These changes are part of Alnylam's strategic evolution in response to its growth and pipeline advancements.
Read more →ALNYAlnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
Alnylam Pharmaceuticals has announced a proposed offering of $500 million in convertible senior notes due 2028. The offering is targeted at qualified institutional buyers and includes the potential for an additional $75 million if initial purchasers exercise their options. The notes will be senior unsecured obligations and may be converted into stock under certain conditions. Alnylam plans to use proceeds for various purposes, including costs associated with capped call transactions and repurchasing existing convertible notes.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
Alnylam Pharmaceuticals has promoted Pushkal Garg to the position of Chief Research and Development Officer, as part of a strategic move to enhance its R&D organization. The company aims to deliver RNA interference (RNAi) therapeutics to all major tissues by the year 2030, indicating a bold goal for growth. With a successful history including the launch of AMVUTTRA and multiple positive Phase 3 results, Alnylam plans to integrate its R&D efforts to accelerate pipeline progress and meet patient needs more effectively.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Comp
Alnylam Pharmaceuticals, Inc. announced the retirement of board member Dr. Phillip A. Sharp, effective May 8, 2025. Dr. Sharp, a co-founder of Alnylam and a pioneer in RNAi research, has played a crucial role in the company's development since its inception in 2002. While he steps down from the Board of Directors, he will continue to contribute to Alnylam as a member of the Scientific Advisory Board. His substantial scientific contributions and accolades, including a Nobel Prize, underline his legacy in the field of medicine.
Read more →ALNY▲ +8.5%on this news
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Produ
Alnylam Pharmaceuticals has announced its preliminary fourth quarter and full year 2024 global net product revenues, reporting $1.646 billion with a 33% annual growth. The company provided guidance for 2025, expecting combined net product revenues to reach between $2.050 billion and $2.250 billion, along with a goal for non-GAAP profitability. CEO Yvonne Greenstreet highlighted a year of anticipated significant advancements in the company's pipeline, indicating a trajectory toward becoming a top-tier biotech firm. Key product launches and clinical developments are expected to contribute to sustainable growth.
Read more →ALNY▼ -10.2%on this news
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241
Alnylam Pharmaceuticals announced its Q4 and full-year 2023 financial results, reporting a 39% increase in global net product revenues, reaching $1.24 billion. The company received FDA clearance for the multi-dosing portion of the ALN-APP Phase 1 study and presented positive results from various clinical studies. Despite strong revenue growth, Alnylam continues to face substantial GAAP operating losses and has a partial clinical hold affecting one of its studies. Looking ahead, Alnylam is positioned for several important milestones in 2024.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Prod
Alnylam Pharmaceuticals has reported preliminary net product revenues of $1,241 million for 2023, reflecting a 39% annual growth. The company maintains a strong cash position, with approximately $2.4 billion in liquidity at year-end. Alnylam has also highlighted positive clinical outcomes from several programs, such as zilebesiran for hypertension and ALN-APP for Alzheimer's disease, which showcase their commitment to advancing RNAi therapeutics. These results underline Alnylam's strategic focus on achieving sustainable innovation and growing its commercial portfolio.
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth C
Alnylam Pharmaceuticals reported its third quarter 2023 financial results, highlighting global net product revenues of $313 million, a 35% increase year-over-year. The company faced some setbacks, including a Complete Response Letter from the FDA concerning ONPATTRO, though it remains optimistic regarding the HELIOS-B Phase 3 study results expected in early 2024. Positive outcomes were reported for the KARDIA-1 Phase 2 study of zilebesiran, with plans for further clinical results in the coming months.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Su
Alnylam Pharmaceuticals announced that the U.S. FDA issued a Complete Response Letter (CRL) for its supplemental New Drug Application for patisiran, designed for treating cardiomyopathy of ATTR amyloidosis. The FDA cited insufficient evidence of clinical meaningfulness, although no safety or quality issues were reported. As a result, Alnylam will not pursue the expanded indication in the U.S., but they remain committed to ongoing studies of vutrisiran and ALN-TTRsc04. Despite the CRL, ONPATTRO is still available for its existing indication for polyneuropathy in patients.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highli
Alnylam Pharmaceuticals reported significant financial results for Q2 2023, achieving net product revenues of $306 million, a 43% year-over-year increase. The company submitted new data to the FDA for patisiran and showcased positive interim results from its Phase 1 study of ALN-APP targeting early-onset Alzheimer's disease. Additionally, Alnylam has partnered with Roche for the global development of zilebesiran. Despite these successes, the company recorded a substantial operating loss compared to the previous year due to rising expenses and decreased revenues from certain products.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercializ
Alnylam Pharmaceuticals has announced a partnership with Roche to co-develop and commercialize zilebesiran, an investigational RNAi therapeutic aimed at treating hypertension in high cardiovascular risk patients. The partnership is expected to enhance the development speed and reach of zilebesiran, utilizing Roche's extensive commercial capabilities and Alnylam's expertise in RNAi therapeutics. Alnylam will receive an upfront payment of $310 million, with potential total deal value reaching up to $2.8 billion, including milestone payments. The collaboration includes shared development costs and plans for a joint clinical trial program.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPAT
Alnylam Pharmaceuticals announced that the FDA will hold an Advisory Committee meeting on September 13, 2023, to discuss the supplemental New Drug Application for patisiran (ONPATTRO), aimed at treating cardiomyopathy associated with ATTR amyloidosis. This follows a scheduled action date of October 8, 2023, under the Prescription Drug User Fee Act. Patisiran is already approved for a related condition, although its safety and efficacy for this new indication have yet to be established.
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth C
Alnylam Pharmaceuticals announced strong financial results for Q1 2023, with global net product revenues reaching $276 million, representing a 48% increase from the previous year. Notably, the company reported positive interim data from a Phase 1 study of its investigational RNAi therapeutic ALN-APP for Alzheimer's disease, marking a significant milestone in CNS therapeutic research. The company reiterated its financial guidance for the year, aiming for between $1.2 billion and $1.285 billion in revenues. Despite these successes, Alnylam reported a GAAP net loss of $174.1 million, indicating ongoing challenges in profitability.
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Mi
Alnylam Pharmaceuticals reported strong financial results for the fourth quarter and full year 2022, with global net product revenues reaching $262 million and $894 million respectively, reflecting a 35% annual growth compared to the previous year. The company submitted a supplemental NDA for ONPATTRO, which has been accepted by the FDA. For 2023, Alnylam forecasts combined net product revenues between $1.2 billion and $1.285 billion. Additionally, the firm highlights continued growth in patient treatments and significant upcoming milestones in its pipeline.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Prod
Alnylam Pharmaceuticals reported preliminary global net product revenues of $894 million for 2022, reflecting a 35% annual growth. The successful launch of AMVUTTRA significantly contributed to a 37% increase in total TTR revenue. The company maintains a strong financial position with approximately $2.2 billion in cash and investments at year-end. The results showcase healthy demand for Alnylam's RNAi therapeutics and solid commercial execution.
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Updates to its Board of Directors - Appoints Carolyn Ber
Alnylam Pharmaceuticals, Inc. has announced changes to its Board of Directors, appointing Nobel Laureate Carolyn Bertozzi, Ph.D., as a new board member. Michael W. Bonney steps down as Executive Chair but remains on the board as a non-independent director, while Amy W. Schulman takes over as Chair of the Board. This leadership transition is aimed at enhancing the priorities of compliance and expanding Alnylam's capacity to serve patients through its RNAi therapeutics. The company is optimistic as it enters key milestones in its P5x25 strategy.
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO , AMVUTTRA , GIVLAARI , and
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO , AMVUTTRA , GIVLAARI , and OXLUMO - Strong First Full Quarter of AMVUTTRA in U.S.: Ac
Read more →ALNY▼ -5%on this news
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Proposed Offering of $900 Million Convertible Senior Not
Christine Regan Lindenboom (Investors and Media) Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes CAMBRIDGE, Mass. September 12, 2022 Alnylam Pharmaceuticals, Inc. ( Alnylam ) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today
Read more →ALNYAlnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO , GIVLAARI , and OXLUMO (3
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO , GIVLAARI , and OXLUMO (33% Growth vs. Same Period Last Received FDA Approval of AM
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for
Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults First and Only FDA-approved Treatment Demonstrating Reversal in Neuropathy Impairment with Subcutaneo
Read more →ALNY▼ -7.6%on this news
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO , GIVLAARI , and OXLUMO - Re
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO , GIVLAARI , and OXLUMO - Reported Positive 18-Month Results from HELIOS-A Phase 3 Stu
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors CAMBRIDGE, Mass., April 5, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that Steven Paul, M.D. is retiring from the Board of Directors effective Apri
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2021 Global Net Product Revenues of $199 Million and $662 Mi
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2021 Global Net Product Revenues of $199 Million and $662 Million, Respectively, Representing 83% Annual Growth Compare
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Prod
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates Achieved Full Year 2021 Preliminary Global Net Product Revenues of $662 Million, Representing 83% Annual Growth Compared to 2020 Maintained Strong Balanc
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President Consistent Scien
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President Consistent Scientific Leadership Focused on Sustainable Innovation CAMBRIDGE, M
Read more →ALNY▼ -15.2%on this news
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlig
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent - Achieved Third Quarter 2021 Combined Net Product Revenues of $167 Million for ONPATTRO , GIVLAARI , and
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highli
Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity Achieved Second Quarter 202
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2021 Combined Net Product Revenues of $136 Million for ONPATTRO , GIVLAARI , and OXLUMO -
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2021 Combined Net Product Revenues of $136 Million for ONPATTRO , GIVLAARI , and OXLUMO - Advanced Vutrisiran toward Market with Positive Results fr
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2020 Global Net Product Revenues of $113 Million and $362 Mi
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2020 Global Net Product Revenues of $113 Million and $362 Million, Respectively - Achieved Regulatory Approvals of OXL
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Launches Alnylam P 5 x25 Strategy for Planned Transition to a Top Five B
Alnylam Launches Alnylam P5x25 Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years New 5-Year Strategy Represents Alnylam s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the Worl
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity Achieved Third Quarter 2020 ONPATTRO Global Net Product Revenue of $82.5 Million, Including Over 20% Quarterly U.
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity Achieved Third Quarter 2020 ONPATTRO Global Net Product Revenue of $82.5 Million, Including Over 20% Quarterly U.S. Growth, with More Than 1,150 Patients on Commercial Ach
Read more →ALNYAlnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity Achieved Second Quarter 2020 ONPATTRO Global Net Product Revenues of $66.5 Million, with More Than 1,050 Patient
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity Achieved Second Quarter 2020 ONPATTRO Global Net Product Revenues of $66.5 Million, with More Than 1,050 Patients on Commercial Product Worldwide - Achieved Second Quarte
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2020 ONPATTRO Net Product Revenues of $66.7 Million with More Than 950 Patients on Commerc
Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2020 ONPATTRO Net Product Revenues of $66.7 Million with More Than 950 Patients on Commercial Product Worldwide - Achieved First Quarter 2020 GIVLAA
Read more →ALNYBlackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics RNAi Represents One of the Most Promising and Rapidly Advancing Frontiers in Biology and D
Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics RNAi Represents One of the Most Promising and Rapidly Advancing Frontiers in Biology and Drug Development Today with Potential to Transform Lives o
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Dicerna Pharmaceuticals, Inc. Media: Amy Trevvett, Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc. Amy Trevvett, Dicerna Pharmaceuticals, Inc. atrevvett@dicerna.com Lauren Stival, Stern Investor Relations, Inc. lauren.stival@sternir.com Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Live
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2019 ONPATTRO (patisiran) Global Net Product Revenues of $55
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter and Full Year 2019 ONPATTRO (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively - As of Year-E
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Joshua Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Pr
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates Achieved Fourth Quarter and Full Year 2019 ONPATTRO (patisiran) Preliminary Global Net Product Revenues of Approximately $56 Million and $166
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Joshua Brodsky (Investors) 617-551-8276 Alnylam Announces Approval of GIVLAARI (givosiran) by the U.S. Food and Drug A
Alnylam Announces Approval of GIVLAARI (givosiran) by the U.S. Food and Drug Administration (FDA) GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Att
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity Achieved Third Quarter 2019 ONPATTRO Global Net Product Revenues of $46.1 Million, Including Initial Sales in Jap
Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity Achieved Third Quarter 2019 ONPATTRO Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Initiated
Read more →ALNYAlnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity Achieved Second Quarter 2019 ONPATTRO Global Net Product Revenues of $38.2 Million with More Than 500 Patients o
Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity Achieved Second Quarter 2019 ONPATTRO Global Net Product Revenues of $38.2 Million with More Than 500 Patients on Commercial Product Worldwide - Reported Positive Results
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer Announce
Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer Announces Planned Appointment of Jeff Poulton Manmeet S. Soni to Resign After a Transition Period CAMBRIDGE, Mass., July 11, 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2019 ONPATTRO Global Net Product Revenues of $26.3 Million with Over 400 Patients on Comme
Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity Achieved First Quarter 2019 ONPATTRO Global Net Product Revenues of $26.3 Million with Over 400 Patients on Commercial Product Worldwide - Achieved Positive Results in ENVISION
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Regeneron Investor Relations Mark Hudson Tel: +1 (914) 847-3482 Mark.hudson@regeneron.com
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) Regeneron Investor Relations Tel: +1 (914) 847-3482 Mark.hudson@regeneron.com Regeneron Media Relations Hala.mirza@regeneron.com Alnylam and Regeneron Announce Broad Collaboration to Discover,
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter 2018 ONPATTRO Global Net Product Revenues of $12.1 Million, with Over 200
Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity Achieved Fourth Quarter 2018 ONPATTRO Global Net Product Revenues of $12.1 Million, with Over 200 Patients on Commercial Product in U.S. and EU as of Year-End 201
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Manmeet Soni (Investors) 617-682-4260 Alnylam Pharmaceuticals Prices Public Offe
Alnylam Pharmaceuticals Prices Public Offering of Common Stock CAMBRIDGE, Mass. January 14, 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO (pa
Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO (patisiran) and Provides Additional Commercial Updates A
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity Obtained FDA and EMA Approvals of ONPATTRO (patisiran) - the First-Ever RNAi Therapeutic - and Launched in U.S. a
Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity Obtained FDA and EMA Approvals of ONPATTRO (patisiran) - the First-Ever RNAi Therapeutic - and Launched in U.S. and EU Received 125 U.S. Patient Start Forms in First Seven Weeks
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO (pati
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO (patisiran) for the Treatment of the Polyneuropathy of Hereditary
Read more →ALNYAlnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity - Received Positive CHMP Opinion for ONPATTRO in Europe for the Treatment of hATTR Amyloidosis in Adult Patients
Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity Received Positive CHMP Opinion for ONPATTRO in Europe for the Treatment of hATTR Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy and On Track for August 11
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity - Presented Positive New Clinical Results from APOLLO Phase 3 Study of Patisiran, and Phase 1 and Phase 1/2 Open-
Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity Presented Positive New Clinical Results from APOLLO Phase 3 Study of Patisiran, and Phase 1 and Phase 1/2 Open-Label Extension (OLE) Studies Advanced Two Additional RNAi Therape
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trad
Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation CAMBRIDGE, Mass., April 20, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity - Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (
Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran,
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces 2018 Corporate Goals Patisiran Expected to be First Commercial
Alnylam Announces 2018 Corporate Goals Patisiran Expected to be First Commercially Available RNAi Therapeutic in Mid 2018 Restructured Sanofi Alliance Provides Alnylam with Global Commercial Footprint for ATTR Givosiran Interim Phase 3 Data Expected in Mid 2018 and U.S. New Dr
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Michael Mason (Investors) 617-551-8327 Alnylam Pharmaceuticals Prices Public Off
Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Michael Mason (Investors) 617-551-8327 Alnylam Pharmaceuticals Prices Public Offering of Common Stock Cambridge, Mass. November 13, 20
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity - Reported Positive APOLLO Phase 3 Results for Patisiran, with Plans for First New Drug Application (NDA) Filing
Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity Reported Positive APOLLO Phase 3 Results for Patisiran, with Plans for First New Drug Application (NDA) Filing by Year-End - Advanced Four RNAi Therapeutics in Late-Stage Develo
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs Company Suspends Fitusiran Dosing due to Th
Read more →ALNYAlnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity - Advanced Industry-Leading RNAi Therapeutics Pipeline, Including Four Programs in Late-Stage Development - - On
Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity - Advanced Industry-Leading RNAi Therapeutics Pipeline, Including Four Programs in Late-Stage Development - - On Track to Report APOLLO Phase 3 Top-Line Results for Patis
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders Compan
Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders Company Appoints Chief Financial Officer and Other Key Roles Ahead of Anticipated Transition to Commercialization Cambridge, Mass. May 9, 2017 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading R
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity - Advanced Industry-Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Three Programs in
Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity Advanced Industry-Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Three Programs in Late-Stage Development - Maintained Strong Balance Sheet with $962
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity - Advanced Industry-Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Thr
Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity Advanced Industry-Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Three Programs in Late-Stage Development; Discontinued Revusiran Deve
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity - Advanced RNAi Therapeutics Pipeline with Eight Active Clinical Programs and Multiple Clinical Data Presentation
Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity Advanced RNAi Therapeutics Pipeline with Eight Active Clinical Programs and Multiple Clinical Data Presentations - Discontinued Revusiran Development, Focusing on Patisiran and
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Discontinues Revusiran Development Decision Does Not Imp
Alnylam Pharmaceuticals Discontinues Revusiran Development Decision Does Not Impact Patisiran or Any Other RNAi Therapeutic Program Company to Host Conference Call Today at 5:00 p.m. ET Cambridge, Mass. October 5, 2016 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Expands and Strengthens Management Team as it Plans for Commercializatio
Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Expands and Strengthens Management Team as it Plans for Commercialization Dr. Yvonne Greenstreet and Dr. Emmanuel Dulac Join A
Read more →ALNYAlnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress - Advanced Two Programs into Phase 1 Clinical Studies: ALN-TTRsc02 for Transthyretin-Mediated Amyloidosis and AL
Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress Advanced Two Programs into Phase 1 Clinical Studies: ALN-TTRsc02 for Transthyretin-Mediated Amyloidosis and ALN-HBV for Chronic Hepatitis B Presented Clinical Data from Patisir
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress - Advances Pipeline of Ten Clinical Stage Programs, with Ten Additional Clinical Data Readouts Anticipated This Y
Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress Pipeline of Ten Clinical Stage Programs, with Ten Additional Clinical Data Readouts Anticipated This Year - Expects to Complete Enrollment of Revusiran Phase 3 ENDEAVOUR Trial i
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress - Advanced Pipeline of Eight Clinical Stage Programs in 2015, with Ten or More Major Clinical Data
Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress Advanced Pipeline of Eight Clinical Stage Programs in 2015, with Ten or More Major Clinical Data Readouts, Start of Fitusiran Phase 3 Trials, and Three New IND Fi
Read more →ALNYAlnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline Company Plans to Adva
Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline Company Plans to Advance Multiple Phase 3 Programs, Including Start of Two Fitusiran Phase 3 Studies, and Expects Ten or More Major Clinical Data Readouts and Three New IND Filings Cambridge, Mass., January 11, 2016 A
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period - Advanced Late-Stage Clinical Pipeline: Patisiran APOLLO Phase 3 Trial on Track to Complete Enrollment in Next 3-4 M
Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period Advanced Late-Stage Clinical Pipeline: Patisiran APOLLO Phase 3 Trial on Track to Complete Enrollment in Next 3-4 Months; if Positive, Expect NDA Presented Positive Clinical Data fo
Read more →ALNYAlnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities - Advanced Pipeline of Seven Investigational Clinical Programs and Presented Positive Clinical Results for Thr
Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities Advanced Pipeline of Seven Investigational Clinical Programs and Presented Positive Clinical Results for Three: Patisiran for Familial Amyloidotic Polyneuropathy (FAP), ALN-A
Read more →ALNYAlnylam Pharmaceuticals, Inc. Michael Mason Vice President, Finance and Treasurer 617-551-8327 Liz Bryan (Media) Spectrum 202-955-6222 x2526 Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, C
Alnylam Pharmaceuticals, Inc. Michael Mason Vice President, Finance and Treasurer 617-551-8327 Liz Bryan (Media) Spectrum 202-955-6222 x2526 Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer Cambridge, Mass., June 8, 2015 Alnylam Ph
Read more →ALNYAlnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress - Launched "Alnylam 2020" Guidance for Advancement and Commercialization of RNAi Therapeutics - - Advanced Multip
Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress Launched "Alnylam 2020" Guidance for Advancement and Commercialization of RNAi Therapeutics - Advanced Multiple Clinical Programs and Presented Evidence for Potential Disease-M
Read more →ALNYAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progress - Introduced Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas,
Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progress Introduced Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or "STArs," and Launched "Alnylam 2020" Guidance for Advancement a
Read more →ALNYAlnylam Pharmaceuticals, Inc. Cynthia Clayton Vice President, Investor Relations and Corporate Communications 617-551-8207 Liz Bryan (Media) Spectrum 202-955-6222 x2526 Alnylam Pharmaceuticals Prices Public Off
Alnylam Pharmaceuticals, Inc. Cynthia Clayton Vice President, Investor Relations and Corporate Communications 617-551-8207 Liz Bryan (Media) Spectrum 202-955-6222 x2526 Alnylam Pharmaceuticals Prices Public Offering of Common Stock Cambridge, Mass., January 20, 2015 Alnylam
Read more →ALNYAlnylam Pharmaceuticals, Inc. Cynthia Clayton Vice President, Investor Relations and Corporate Communications 617-551-8207 Liz Bryan (Media) Spectrum 202-955-6222 x2526 Alnylam Launches Alnylam 2020 Guidance fo
Alnylam Pharmaceuticals, Inc. Cynthia Clayton Vice President, Investor Relations and Corporate Communications 617-551-8207 Liz Bryan (Media) Spectrum 202-955-6222 x2526 Alnylam Launches Alnylam 2020 Guidance for Advancement and Commercialization of RNAi Therapeutics By En
Read more →ALNYAlnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress - Reported Six-Month Clinical Data from Phase 2 Open-Label Extension (OLE) Study with Patisiran, Showing Tolerabi
Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress Reported Six-Month Clinical Data from Phase 2 Open-Label Extension (OLE) Study with Patisiran, Showing Tolerability, Sustained Transthyretin (TTR) Knockdown, and Promising Initi
Read more →Competitive Position
How ALNY ranks across every disease it competes inCompetitive Position is a premium feature
See how ALNY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial